Our Vision

CMAC’s vision is to revolutionise the way pharmaceuticals and high value products are made.  The approaches developed and adopted within CMAC have been developed through close collaboration with industry and the support of its Tier 1 partners, which includes GlaxoSmithKline, AstraZeneca, Bayer, Lilly, Novartis, Roche and Takeda.  Established in 2011, the CMAC has a £150m funding portfolio and currently comprises more than 130 staff and researchers, including academics, post docs, and more than 45 PhD students, as well as an experienced support team.

CMAC

• conducts world class research in continuous manufacturing and advanced crystallisation;
• conducts fundamental research;
• develops new solutions to company specific problems;
• delivers measurable successes that are of real benefit to society;
• creates commercial opportunities for start-ups and major global companies;
• produces a talent pipeline of highly skilled multi-disciplinary staff;
• influences policy, government, and regulators;
• understands and integrates with the broader supply chain context
• collaborates with world class business and academia on an international basis.

Our Partners

News